ライフサイエンスコーパス: inhaled corticosteroid

1 e asthma that are treated with high doses of inhaled corticosteroids.

2 ave higher morbidity and reduced response to inhaled corticosteroids.

3 thelial cells recovered after treatment with inhaled corticosteroids.

4 evious 12 months and who were not on regular inhaled corticosteroids.

5 respiratory symptoms to predict response to inhaled corticosteroids.

6 es) and whether or not patients had received inhaled corticosteroids.

7 ounts less than 2% have a poorer response to inhaled corticosteroids.

8 ent failure, particularly in subjects taking inhaled corticosteroids.

9 with combined long-acting beta2-agonists and inhaled corticosteroids.

10 osinophilia despite treatment with high-dose inhaled corticosteroids.

11 ome, environmental tobacco smoke, and use of inhaled corticosteroids.

12 overall mortality associated with the use of inhaled corticosteroids.

13 mptomatic despite treatment with medium-dose inhaled corticosteroids.

14 eterol 50 mug, or placebo, while maintaining inhaled corticosteroids.

15 h an asthma exacerbation and were on regular inhaled corticosteroids.

16 dherence with controller medications such as inhaled corticosteroids.

17 a refractory to maximally indicated doses of inhaled corticosteroids.

18 All patients continued their inhaled corticosteroids.

19 d severity of asthma and a lower response to inhaled corticosteroids.

20 as an add-on therapy in adult asthmatics on inhaled corticosteroids.

21 st, and 5.6% (3.1-9.9) had been treated with inhaled corticosteroids.

22 may partly explain their reduced response to inhaled corticosteroids.

23 r rapid relief of symptoms, and daily use of inhaled corticosteroids.

24 ss in adult stable asthmatic patients taking inhaled corticosteroids.

25 ators (16.7%; 95% CI: 16.1%-17.3%; p<0.001), inhaled corticosteroids (21.5%; 95% CI: 20.7%-22.3%; p<0

26 mproved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and pr

27 s observed among 5594 new users of LABAs and inhaled corticosteroids (3174 deaths [36.4%]; 2420 COPD

28 In patients not treated with inhaled corticosteroids, 40 (3.8%) patients with less th

29 un-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized.

30 r a short-acting beta2-agonist and 41.2% for inhaled corticosteroids; 76.5% were managed with asthma

31 FE vs. 30% IE vs. 13% WNE, P < .001) and use inhaled corticosteroids (77% FE vs. 15% IE vs. 18% WNE,

32 nd diffuse panbronchiolitis and treated with inhaled corticosteroids, a long-acting beta agonist, and

33 In the intention-to-treat analysis, inhaled corticosteroid adherence was 25.4% higher in the

34 xhaled nitric oxide (FeNO) in 17 studies for inhaled corticosteroid adherence.

35 -agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient.

36 article formulations (smaller than 2 mum) of inhaled corticosteroids alone or in combination with lon

37 lus orally inhaled corticosteroids to orally inhaled corticosteroids alone, and nasally inhaled corti

38 nist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS

39 iven orally once daily together with a fixed inhaled corticosteroid and longacting beta2 agonist comb

40 of frequent and severe exacerbations despite inhaled corticosteroid and longacting beta2 agonist ther

41 for exacerbations, even in combination with inhaled corticosteroid and longacting beta2 agonist trea

42 ons, we analysed 214 patients (114 extrafine inhaled corticosteroids and 100 placebo).

43 ed, including 208 (44%) prescribed high-dose inhaled corticosteroids and 122 (31%) with severe asthma

44 in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controll

45 upport further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention

46 Early treatment with inhaled corticosteroids and beta agonists may reduce pro

47 esponder group who were exposed to high-dose inhaled corticosteroids and frequent long-acting beta-ag

48 t as allergic patients using antihistamines, inhaled corticosteroids and IgE antagonists.

49 The association of use of inhaled corticosteroids and incident pneumonia is substa

50 Dispensed inhaled corticosteroids and inhaled beta-agonists were a

51 patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting beta-agonists.

52 Inhaled corticosteroids and long-acting beta2-agonist co

53 least two exacerbations while on high-dosage inhaled corticosteroids and long-acting beta2-agonists (

54 tion for high-intensity treatment (high-dose inhaled corticosteroids and long-acting beta2-agonists o

55 Combination therapy, including inhaled corticosteroids and long-acting beta2-agonists,

56 rolled asthma using medium-dose or high-dose inhaled corticosteroids and longacting beta agonists, wi

57 Current therapies based on inhaled corticosteroids and longacting beta2 agonists ar

58 fect in patients using fixed combinations of inhaled corticosteroids and longacting beta2 agonists is

59 avir) can result in systemic accumulation of inhaled corticosteroids and might increase pneumonia ris

60 lammation and might respond to high doses of inhaled corticosteroids and newly developed specific ant

61 rimary outcomes were adherence to preventive inhaled corticosteroids and number of days absent from s

62 r to enrollment, despite receiving high-dose inhaled corticosteroids and other controller(s), plus om

63 litation and bronchodilators with or without inhaled corticosteroids and oxygen; those randomized to

64 dentify patients most likely to benefit from inhaled corticosteroids and targeted anti-immunoglobulin

65 th asthma aged 6 to 16 years taking low-dose inhaled corticosteroids and with serum 25-hydroxyvitamin

66 60-90% predicted despite use of medium-dose inhaled corticosteroids, and had never smoked or were ex

67 of long-acting maintenance bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation de

68 magnesium sulfate, anti-inflammatory agents, inhaled corticosteroids, and short-acting bronchodilator

69 Inhaled corticosteroids are commonly prescribed for pati

70 Inhaled corticosteroids are commonly used in the treatme

71 Inhaled corticosteroids are important in the management

72 While bronchodilators and inhaled corticosteroids are the mainstay of asthma treat

73 Inhaled corticosteroids are the most commonly used contr

74 Few treatments are available and inhaled corticosteroids are the recommended preventer tr

75 Inhaled corticosteroids are widely used in chronic obstr

76 nical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and

77 o salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a posit

78 ciated with increased risk of treatment with inhaled corticosteroids at age 7 years (adjusted odds ra

79 able asthmatics that were being treated with inhaled corticosteroids at the time of the study.

80 uately controlled by medium-to-high doses of inhaled corticosteroid based therapy and who had blood e

81 with good responders and poor responders to inhaled corticosteroids based on a subset of 145 white c

82 il counts who are inadequately controlled on inhaled corticosteroid-based therapy.

83 A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps

84 t asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure i

85 lergic inflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic cort

86 matching, there were 8712 new users of LABA-inhaled corticosteroid combination therapy and 3160 new

87 nergic medication, newly prescribed LABA and inhaled corticosteroid combination therapy, compared wit

88 ncy than either their monocomponents or LABA/inhaled corticosteroid combinations in patients at low a

89 GROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-

90 cting beta2-agonists or medium- to high-dose inhaled corticosteroids combined with oral corticosteroi

91 The ongoing use of inhaled corticosteroids did not increase the risk of hos

92 sthma Control Questionnaire score, 0.76; and inhaled corticosteroid dosage, 550 mug/d.

93 s with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the

94 ing beta(2) agonist therapy to a maintenance inhaled corticosteroid dose that causes the same magnitu

95 ypes was not influenced by change in oral or inhaled corticosteroid dose, nor by the number of exacer

96 elated (P < .05 for all) positively with the inhaled corticosteroid dose, total number of controller

97 However, a fall in FeNO following supervised inhaled corticosteroid dosing could indicate previous po

98 Use of inhaled corticosteroids during the first trimester of pr

99 have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chr

100 In patients treated with inhaled corticosteroids, events occurred in 107 (4.5%) v

101 ful biomarker of the long-term effect of the inhaled corticosteroid fluticasone furoate on exacerbati

102 nochemical domains of powders containing the inhaled corticosteroid fluticasone propionate and long-a

103 Across all doses of inhaled corticosteroids, fluticasone furoate and vilante

104 ticle salmeterol dry powder twice daily plus inhaled corticosteroid for 1 to 2 weeks with a 1- to 2-w

105 The short-term benefits of inhaled corticosteroids for patients with chronic obstru

106 safety of long-acting beta-agonists added to inhaled corticosteroids for the treatment of persistent

107 with dyspnea and cough had been treated with inhaled corticosteroids for X-15 years, but her symptoms

108 practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis

109 bination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-a

110 the change in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group

111 mportantly, investigators have reported that inhaled corticosteroids had a limited effect on airway i

112 rse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperres

113 However, inhaled corticosteroids have been linked with an increas

114 RATIONALE: Inhaled corticosteroids have been shown to decrease exac

115 Inhaled corticosteroids have been the foundation for ast

116 high blood eosinophil counts despite use of inhaled corticosteroids have reported improved outcomes

117 Inhaled corticosteroids have substantial risks, includin

118 hese observations suggest a double effect of inhaled corticosteroids (i.e., an adverse effect plus an

119 esponsiveness to step-up to a higher dose of inhaled corticosteroid (ICS step-up therapy) or addition

120 Extra-fine particle formulations of inhaled corticosteroid (ICS) are associated with improve

121 contribute to uncontrolled asthma; negative inhaled corticosteroid (ICS) beliefs and complementary a

122 umab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall e

123 been a general expectation that early use of inhaled corticosteroid (ICS) could change the natural hi

124 izumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were eval

125 pium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy.

126 Although inhaled corticosteroid (ICS) medication is considered th

127 d n = 20 control subjects) and prediction of inhaled corticosteroid (ICS) response (n = 71 asthmatic

128 ty (OW) is linked to worse asthma and poorer inhaled corticosteroid (ICS) response in older children

129 Inhaled corticosteroid (ICS) therapy is a mainstay of tr

130 cs who smoke cigarettes respond less well to inhaled corticosteroid (ICS) therapy than asthmatics who

131 c asthma and the impact on the microbiota of inhaled corticosteroid (ICS) treatment administered to I

132 tion in sputum basophils following increased inhaled corticosteroid (ICS) treatment.

133 mptoms and a low risk of asthma attacks with inhaled corticosteroid (ICS) treatment.

134 ssociation was modified by smoking status or inhaled corticosteroid (ICS) use.

135 The rate of discontinuation of inhaled corticosteroid (ICS) was 6/17 in SCIT + vitamin

136 Their use of inhaled corticosteroid (ICS) was standardized and adjust

137 cerbations.Objectives: To understand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT

138 endronate can reduce LABA-associated LOBP in inhaled corticosteroid (ICS)-treated patients.

139 ay contribute to the clinical superiority of inhaled corticosteroid (ICS)/LABA combinations in asthma

140 nt guidelines were updated to recommend that inhaled corticosteroid (ICS)/long-acting beta (2)-adreno

141 The combination drug of inhaled corticosteroid (ICS)/long-acting beta2 agonist i

142 ized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (

143 nists (LABAs) (n = 3174), 1 RCT of LABAs and inhaled corticosteroids (ICS) (n = 1097), 5 RCTs of the

144 mechanisms underlying hyperinflation and how inhaled corticosteroids (ICS) affect this important aspe

145 e of exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood eosinop

146 BACKGROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroid

147 Side-effect concerns impede adherence with inhaled corticosteroids (ICS) and often underlie poor as

148 Inhaled corticosteroids (ICS) are a mainstay of treatmen

149 Low-dose inhaled corticosteroids (ICS) are highly effective for r

150 Rationale: Inhaled corticosteroids (ICS) are key treatments for con

151 Inhaled corticosteroids (ICS) are the most widely prescr

152 exacerbation in stable asthmatics who reduce inhaled corticosteroids (ICS) compared to those who main

153 re two principal agents that can be added to inhaled corticosteroids (ICS) for patients with asthma t

154 The NHLBI Expert Panel Report 3 recommends inhaled corticosteroids (ICS) for patients with moderate

155 h difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory asthma is

156 eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic o

157 Inhaled corticosteroids (ICS) increase community-acquire

158 Daily dose of inhaled corticosteroids (ICS) inversely correlated with

159 The clinical response to inhaled corticosteroids (ICS) is associated with single

160 Increasing the dose of inhaled corticosteroids (ICS) is commonly used at early

161 ic obstructive pulmonary disease (COPD) with inhaled corticosteroids (ICS) is controversial, because

162 been receiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus lon

163 Inhaled corticosteroids (ICS) target gene transcription

164 logy of "low," "medium," and "high" doses of inhaled corticosteroids (ICS) to define daily maintenanc

165 Use of inhaled corticosteroids (ICS) was associated with lower

166 In patients on high-dose inhaled corticosteroids (ICS) with type 2-high asthma (s

167 ts with asthma on maintenance treatment with inhaled corticosteroids (ICS).

168 se to salmeterol was dependent on the use of inhaled corticosteroids (ICS).

169 most commonly prescribed controller therapy, inhaled corticosteroids (ICS).

170 ase control, even while taking high doses of inhaled corticosteroids (ICS).

171 mendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therap

172 Inhaled corticosteroids (ICSs) are considered the most e

173 istent asthma during pregnancy when low-dose inhaled corticosteroids (ICSs) are insufficient include

174 Inhaled corticosteroids (ICSs) are the preferred treatme

175 Inhaled corticosteroids (ICSs) are used extensively in t

176 Inhaled corticosteroids (ICSs) are widely used as first-

177 Inhaled corticosteroids (ICSs) are widely used in COPD,

178 Variability in response to inhaled corticosteroids (ICSs) can result in less than o

179 Characteristics of inhaled corticosteroids (ICSs) differ, but data comparin

180 s), while anti-inflammatory maintenance with inhaled corticosteroids (ICSs) has been reserved for pat

181 dynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measurin

182 sm of asthma in patients receiving high-dose inhaled corticosteroids (ICSs) is uncertain.

183 of higher-level medication: medium/high-dose inhaled corticosteroids (ICSs) or ICSs + add-on medicati

184 A allele among the 637 children treated with inhaled corticosteroids (ICSs) plus LABAs but not for tr

185 to obtain diagnoses and treatment), (2) use inhaled corticosteroids (ICSs) properly, and (3) underst

186 atment of mild asthma is regular maintenance inhaled corticosteroids (ICSs) with a short-acting beta-

187 opium is efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other mai

188 d followed by 3 crossover periods with daily inhaled corticosteroids (ICSs), daily leukotriene recept

189 tic patients using LABA-containing products, inhaled corticosteroids (ICSs), leukotriene modifiers, s

190 When compared with placebo, only inhaled corticosteroids (ICSs), with or without a long-a

191 rican and white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respective

192 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

193 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

194 They consider the indications for inhaled corticosteroids in COPD, when inhaled corticoste

195 r single long-acting bronchodilators or LABA/inhaled corticosteroids in decreasing exacerbation.

196 ancing the beneficial and adverse effects of inhaled corticosteroids in individuals with COPD--is dif

197 ount is a promising biomarker of response to inhaled corticosteroids in patients with COPD.

198 aled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific re

199 might be important predictors of response to inhaled corticosteroids in preschool children, these rel

200 to significant improvements in adherence to inhaled corticosteroids in school-aged children with ast

201 A methylation was analysed in individuals on inhaled corticosteroids in three independent and ethnica

202 ither as monotherapy or as add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 per

203 al corticosteroids and omalizumab to regular inhaled corticosteroid inhalation failed to relieve symp

204 tions either enabled to support adherence to inhaled corticosteroids (intervention group) or disabled

205 Response to inhaled corticosteroids is highly variable, and the asso

206 inhaled bronchodilators, whereas the role of inhaled corticosteroids is less clear.

207 f acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for pers

208 mechanisms of increased pneumonia risk with inhaled corticosteroids is urgently needed to clarify th

209 o was complicated with COPD and treated with inhaled corticosteroid, long-acting beta2 agonist, long-

210 xed-dose combination inhaler therapy with an inhaled corticosteroid, long-acting beta2-agonist, and l

211 whereas severe disease can be refractory to inhaled corticosteroids, long-acting beta-agonists, and

212 d only if there is a progressive increase in inhaled corticosteroid/long-acting beta(2) agonist thera

213 phils as a predictor of responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combina

214 ts of stepping up patients with COPD from an inhaled corticosteroid/long-acting beta2-agonist combina

215 were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting beta2-agonist flutica

216 tenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting beta2-agonist therapy

217 izations in the previous year, and receiving inhaled corticosteroid/long-acting beta2-agonist with or

218 nistic insight as to how adding a LABA to an inhaled corticosteroid may improve clinical outcomes in

219 erent deficient IFN responses to rhinovirus, inhaled corticosteroids might interact synergistically w

220 agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling diseas

221 The potential adverse effects of inhaled corticosteroids need to be weighed against the l

222 The effects of inhaled corticosteroids on growth seem to be dependent o

223 literature to further explore the effects of inhaled corticosteroids on incident pneumonia and mortal

224 medication use (leukotriene antagonists and inhaled corticosteroids) on the following 4 asthma-relat

225 r development, mainly in combination with an inhaled corticosteroid or a long-acting antimuscarinic a

226 pulations that are more likely to respond to inhaled corticosteroids or biologics.

227 These findings suggest that children using inhaled corticosteroids or inhaled beta-agonists might b

228 Newly prescribed combination LABAs and inhaled corticosteroids or LABAs alone.

229 every year older than age 30 in subjects on inhaled corticosteroids (OR per year, 1.03; CI, 1.01-1.0

230 ombination of long-acting beta2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85).

231 mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; po

232 INCS sprays when patients were not on orally inhaled corticosteroids, or when corticosteroid medicati

233 improvement despite treatment with high dose inhaled corticosteroids, oral corticosteroids and azathi

234 acerbations may benefit from the addition of inhaled corticosteroids, particularly those with elevate

235 quately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting beta-agonist.

236 on of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting beta(2)-agonist

237 vals in addition to standard care (high-dose inhaled corticosteroids plus >/=1 additional controller

238 receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

239 led persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

240 asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

241 uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonist

242 previous year despite dual inhaled therapy (inhaled corticosteroids plus long-acting beta(2)-agonist

243 inic antagonists) or triple inhaled therapy (inhaled corticosteroids plus long-acting beta(2)-agonist

244 nd exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting beta2 agonists.

245 ble safety profile, and hence in addition to inhaled corticosteroids plus long-acting beta2-agonist t

246 that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medication

247 e screening despite regular use of high-dose inhaled corticosteroids plus other controller medicines.

248 ity, have resulted in a variable approach to inhaled corticosteroid prescribing by medical practition

249 (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 mug, two puffs twice pe

250 Once-daily tiotropium add-on to medium-dose inhaled corticosteroids reduces airflow obstruction and

251 ntervention condition were triggered when an inhaled corticosteroid refill was due or overdue.

252 School-supervised use of a once-daily inhaled corticosteroid regimen (supervised therapy) can

253 ol Questionnaire), lung function (FEV1), and inhaled corticosteroid requirement.

254 g with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmeterol/fluticasone combinatio

255 minimise any adverse effects, treatment with inhaled corticosteroids should always aim to reach the l

256 ns for inhaled corticosteroids in COPD, when inhaled corticosteroids should be withdrawn, and what ot

257 loped a brief version (ICQ-S) of the 57-item Inhaled Corticosteroids side-effect Questionnaire (ICQ)

258 r more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of les

259 In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation

260 ears to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify pat

261 wth, and that children who receive long-term inhaled corticosteroid therapy for asthma have height de

262 able to intervention; long-term therapy with inhaled corticosteroid therapy is safer than frequent bu

263 hma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.

264 the absence oral corticosteroid use while on inhaled corticosteroid therapy.

265 were no more likely than those treated with inhaled corticosteroids to experience adverse outcomes.

266 be involved in a reduction in the ability of inhaled corticosteroids to impair control of airway infl

267 S sprays to placebo, INCS sprays plus orally inhaled corticosteroids to orally inhaled corticosteroid

268 The results do not support restriction of inhaled corticosteroids to patients with symptoms on mor

269 y inhaled corticosteroids alone, and nasally inhaled corticosteroids to placebo.

270 randomly assigned 294 patients to extrafine inhaled corticosteroid treatment (n=148) or placebo (n=1

271 lation of IL12B and CORT are associated with inhaled corticosteroid treatment response in persistent

272 omorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermitt

273 58 adult patients with mild asthma having no inhaled corticosteroid treatment, and 10 adult patients

274 asthma, to aeroallergen sensitization, or to inhaled corticosteroid treatment.

275 and raised sputum eosinophil counts despite inhaled corticosteroid treatment.

276 in their risk of pneumonia, irrespective of inhaled corticosteroid treatment.

277 ponse to Leukotriene Receptor Antagonist and Inhaled Corticosteroid trial).

278 e previous year, and previously treated with inhaled corticosteroid (TRIMARAN: medium dose; TRIGGER:

279 Control Questionnaire score of 1) 0.63; and inhaled corticosteroid use 0.89.

280 ious exacerbation frequency, smoking status, inhaled corticosteroid use at baseline, body-mass index

281 Despite the robust association of inhaled corticosteroid use with increased risk of pneumo

282 cohort (n = 650), adjusting for smoking and inhaled corticosteroid use, and verified results in thre

283 A history of inhaled corticosteroid use, but not atopic status, mite

284 After a run-in period to control for inhaled corticosteroid use, induced sputum was collected

285 Secondary outcomes included inhaled corticosteroid use, outpatient physician's offic

286 n those with milder asthma in the setting of inhaled corticosteroid use.

287 ospitalization associated with asthma and/or inhaled corticosteroid use.

288 oportion of participants in whom the dose of inhaled corticosteroid was reduced halfway through the t

289 the proportion of participants whose dose of inhaled corticosteroid was reduced, or the cumulative fl

290 New use of LABAs and inhaled corticosteroids was associated with a modestly r

291 Adherence with inhaled corticosteroids was similarly high for both inco

292 and winter, whereas a higher requirement for inhaled corticosteroids was the strongest predictor in s

293 ent asthma diagnosis and prescription for an inhaled corticosteroid were randomized to the computeriz

294 or's diagnosis of asthma who were prescribed inhaled corticosteroids were allocated to one of 3 treat

295 Inhaled corticosteroids were measured directly in the bl

296 Thirty-nine adult asthmatics on inhaled corticosteroids were randomized to receive activ

297 The dosages of inhaled corticosteroids were reduced.

298 s of exacerbation had different responses to inhaled corticosteroids when compared with the other clu

299 Similarly, the use of inhaled corticosteroids with or without systemic cortico

300 It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves ou